DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,755 filers reported holding DANAHER CORPORATION in Q1 2021. The put-call ratio across all filers is 0.86 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $72,675 | +2.0% | 292,925 | -1.4% | 0.41% | +6.5% |
Q2 2023 | $71,272 | -3.0% | 296,966 | +1.8% | 0.38% | -10.1% |
Q1 2023 | $73,507 | -0.3% | 291,648 | +5.0% | 0.42% | -8.2% |
Q4 2022 | $73,707 | -99.9% | 277,698 | +18.0% | 0.46% | +13.8% |
Q3 2022 | $60,761,000 | +6.4% | 235,242 | +4.4% | 0.41% | +9.7% |
Q2 2022 | $57,104,000 | -0.8% | 225,243 | +14.7% | 0.37% | +15.6% |
Q1 2022 | $57,586,000 | +13.1% | 196,317 | +26.9% | 0.32% | +27.9% |
Q4 2021 | $50,903,000 | +0.3% | 154,716 | -7.1% | 0.25% | -5.6% |
Q3 2021 | $50,729,000 | +13.4% | 166,629 | 0.0% | 0.27% | +14.2% |
Q2 2021 | $44,717,000 | +29.1% | 166,629 | +8.3% | 0.23% | +18.3% |
Q1 2021 | $34,643,000 | +4.4% | 153,913 | +3.0% | 0.20% | -2.5% |
Q4 2020 | $33,178,000 | +4.6% | 149,358 | +1.4% | 0.20% | -12.9% |
Q3 2020 | $31,731,000 | -38.4% | 147,358 | -49.4% | 0.23% | +5.9% |
Q2 2020 | $51,514,000 | +19866.7% | 291,316 | +11035.9% | 0.22% | +4280.0% |
Q2 2018 | $258,000 | -56.1% | 2,616 | -56.4% | 0.01% | -16.7% |
Q1 2018 | $588,000 | +5.8% | 6,000 | 0.0% | 0.01% | -14.3% |
Q4 2017 | $556,000 | -93.7% | 6,000 | -93.7% | 0.01% | -95.9% |
Q4 2015 | $8,889,000 | – | 95,702 | – | 0.17% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |